EADV 2026 Day 4: Precision Medicine, Real-World Evidence, and the Future of Dermatologic Care

The fourth and final day of the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, shifted the conversation from individual clinical trial readouts toward a broader question: how can dermatologists translate an increasingly complex therapeutic landscape into more personalized patient care?

Saturday's scientific program brought together discussions of molecular profiling, genetics, real-world evidence, clinical trial design, inflammatory skin disease, and subspecialty advances. Together, the sessions offered a look at how precision medicine may increasingly influence dermatologic diagnosis and treatment selection.

Here are some of the notable themes from the final day of EADV 2026.

Molecular Profiling Could Move Dermatology Beyond Disease Labels

Personalized treatment for immune-mediated inflammatory diseases (IMIDs) of the skin took center stage during the final EADV plenary session.

Michel Gilliet, MD, presented a precision medicine approach using transcriptomic analysis of skin biopsies to characterize the dominant immune pathways underlying individual patients' disease.

The approach maps inflammatory activity across immune modules including Th17, Th2, Th1, type I interferon, neutrophilic, macrophagic, and eosinophilic inflammation.

Such molecular profiling could have implications beyond treatment selection. Clinically overlapping conditions, including difficult cases of erythroderma and palmoplantar disease, may potentially be differentiated according to their molecular signatures.

Profiling could also help explain why targeted treatments fail in some patients. When the pathway targeted by a therapy does not correspond with the dominant pathway driving a patient's disease—or when that pathway changes during treatment—molecular information may provide a rationale for adjusting therapy.

The approach represents a potential shift away from treating patients solely according to diagnostic labels and toward selecting therapy based on the underlying biology of an individual's disease.

Genetics Continues to Reshape Understanding of Atopic Dermatitis

The final plenary also examined how advances in genetics are improving understanding of atopic eczema.

Sara Brown, MD, PhD, discussed the molecular and genetic mechanisms contributing to atopic eczema and related cutaneous and systemic disorders.

Genetic discoveries have helped clarify the role of skin barrier dysfunction and inflammatory pathways in AD while contributing to the development of increasingly targeted anti-inflammatory treatments.

As the AD treatment landscape continues to expand, understanding differences in disease biology could become increasingly relevant to identifying which patients may respond best to specific therapeutic approaches.

The discussion complemented a broader theme running throughout EADV 2026: AD is not a single uniform disease, and future management may increasingly incorporate molecular, genetic, clinical, and patient-specific characteristics.

Real-World Evidence Meets Clinical Trials in AD

Atopic dermatitis remained a focus during the final afternoon of EADV through a dedicated International Eczema Council session examining the relationship between randomized clinical trials and real-world data.

The program explored practical lessons from clinical trial design, pediatric research, biomarkers, disease heterogeneity, treatment patterns, safety, and regulatory-grade real-world evidence.

Randomized controlled trials remain essential for establishing the efficacy and safety of new therapies, but real-world evidence can provide additional information about how treatments perform across more diverse patient populations and over longer periods of routine clinical care.

As more biologics and small molecules become available for AD, combining these forms of evidence may become increasingly important for answering questions that extend beyond initial regulatory trials, including treatment sequencing, long-term safety, persistence, and outcomes in patient populations that may be underrepresented in clinical studies.

Stress and the Brain-Skin Connection Receive New Attention

Another final-day plenary challenged clinicians to consider the relationship between central nervous system signaling and inflammatory skin disease.

The presentation examined whether lessons from fibromyalgia and central threat-processing pathways could help researchers better understand stress-responsive dermatologic conditions.

Stress has long been associated with exacerbations of conditions including psoriasis, AD, chronic spontaneous urticaria, alopecia areata, and chronic itch.

The discussion proposed looking beyond inflammation occurring exclusively at the skin level and considering how central stress pathways may amplify or sustain symptoms.

Although the concept remains an evolving area of research, it reflects increasing interest in the interconnected neurologic, immunologic, and psychological mechanisms contributing to chronic dermatologic disease.

Subspecialty Sessions Broaden the Final-Day Conversation

The final afternoon of EADV 2026 also featured dedicated subspecialty programming, bringing international dermatology organizations together to address focused areas of clinical practice.

Topics included vitiligo, alopecia areata, lichen planopilaris, pediatric and complex medical dermatology, laser treatment, and other areas spanning medical and procedural care.

These sessions complemented the larger therapeutic studies presented throughout the congress by focusing on practical clinical challenges and diseases that may receive less attention in major late-breaking sessions.

The breadth of the programming also underscored the increasingly multidisciplinary nature of dermatology, as advances in immunology, genetics, technology, and procedural treatment continue to reshape multiple areas of the specialty.

EADV 2026 Ends With a Focus on Individualized Care

Across 4 days in Vienna, EADV 2026 showcased an expanding range of biologics, oral therapies, investigational mechanisms, long-term clinical data, digital technologies, and emerging approaches to diagnosis.

The final day's emphasis on precision medicine provided a fitting conclusion to those developments.

As dermatologists gain more therapeutic options, the challenge is increasingly shifting from whether an effective treatment exists to determining which treatment is most appropriate for a particular patient.

Molecular immune profiling, genetic research, biomarkers, and real-world evidence could eventually help clinicians make those decisions with greater precision.

From late-breaking therapeutic advances to broader discussions of personalized care, EADV 2026 highlighted a field moving toward increasingly targeted treatment—not only at the level of the disease, but potentially at the level of the individual patient.